Rituximab Therapy in Patients With Treatment Refractory Hypersenstivity Pneumonitis

Summary

Hypersensitivity pneumonitis (HP) presents with a highly variable clinical course, and Traditional treatment involves systemic corticosteroids in conjunction with strict avoidance of the offending antigen. However, a subset of patients with progressive disease remains unresponsive to conventional therapies. The objective of this study is to evaluate the therapeutic potential of Rituximab in individuals with refractory hypersensitivity pneumonitis who did not respond to conventional immunosuppressive therapy and antigen avoidance. Assessing FVC at three intervals: six months prior to the initiation of Rituximab therapy (M-6), at the time of treatment initiation (M0), and six months afterward (M+6).

Timeline

Start

2023-06-01

Primary completion

2025-01-31

Completion

2025-01-31

Publications

• Akl Y, Kaddah SZ, Nassar SM, El Said RK. Rituximab therapy in patients with treatment-refractory hypersensitivity pneumonitis. Sci Rep. 2025 Oct 17;15(1):36460. doi: 10.1038/s41598-025-21463-y.

Drugs

Indications